EuroPCR 2022: Late-breaking Science Video Collection

Published: 13 May 2022

  • Views:

    Views Icon 1127
  • Likes:

    Heart Icon 7


Full programme

Part 2 of 2

EuroPCR 22: CRUZ-HBR Indicates Use Of Supraflux™ Cruz Stent Is Favourable

David Leistner

View Transcript Download Transcript


Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science trials and spotlight questions that could change treatment strategies in interventional cardiology.

Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Part 1

View from the Thoraxcenter

In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their take on the most anticipated late-breaking science form EuroPCR 2022.

Part 2

Expert Interviews

Short, accessible Expert Interviews with select faculty focusing on the results, applicability, and impact on future research.
19 sessions
EuroPCR 22: AQVA Study Shows Superiority in QFR-Based Virtual PCI Arm Watch now
EuroPCR 22: Patient-Level Pooled Analysis of Ultrasound RDN in radiance-HTN SOLO & Trio Watch now
EuroPCR 22: Optimize PRO Interim Analysis Finds New Technique is "Best-in-Class" Watch now
EuroPCR 22: MASTER-DAPT Sub-Analysis Shows Consistent Results in Complex PCI Patients Watch now
EuroPCR 22: CRUZ-HBR Indicates Use Of Supraflux™ Cruz Stent Is Favourable Watch now
EuroPCR 22: ASTRO-TAVI Shows Improved Neurological Outcomes With Neurointervention Watch now
EuroPCR 22: Short-Term Clinical Outcomes of ACURATE neo2™ Watch now
EuroPCR 22: DECISION QFR Shows Increased Practicability and Shorter Procedure Time for Revasc. Watch now
EuroPCR 22: SYNERGY™ Non-inferior to BioMatrix NeoFlex in OCT SORT-OUT VIII Watch now
EuroPCR 22: ROLEX Study Finds Promising Results in CAD Pts With the Resolute Onyx Watch now
EuroPCR 22: Balloon Vs Self-Expanding Valves in Valve-in-Valve TAVI Watch now
EuroPCR 22: MitraClip in Atrial Functional Mitral Regurgitation Watch now
EuroPCR 22: SCB with Micro-Reservoir Technology in Coronary Lesions Watch now
EuroPCR 22: FORWARD PRO Study Shows No Durability Issues After 3 Years Watch now
EuroPCR 22: DEB & DES in the Treatment of Diffuse CAD Watch now
EuroPCR 22: EASTBOURNE Registry indicates Satefy of Sirolimus-Coated Balloon Watch now
EuroPCR 22: JenaValve TAVR System for the Treatment of Aortic Regurgitation Watch now
EuroPCR 22: Transcatheter Tricuspid Valve Repair with PASCAL System Watch now
EuroPCR 2022: ALIGN-EFS Finds 100% Procedural Success Rate Using JenaValve Trilogy in Pts With AS Watch now

Faculty Biographies

David Leistner

David Leistner

Managing Senior Physician

Prof Leistner is a Managing Senior Physician at the Clinic for Cardiology and Angiology, Charité Berlin, Campus Benjamin Franklin.

View full profile


- My name is professor David Leistner, I'm head of the interventional cardiology, at Charité Universitätsmedizin, Berlin in Germany. And I presented at the EuroPCR 2022, the primary results of the CRUZ-HBR study.

Aim of This Study

So, the aim of the study was to assess the performance of the ultra thin strut Supraflux Cruz Stent in a large broad cohort of all-comer patients with a certain number, of about one third, high bleeding risk HBR patients.

The Supraflux Cruz Stent

So we investigated the Supraflux Cruz drug-eluting stent, which is a ultra thin strut stent, drug-eluting stent, with strut thickness of about 60 micrometres, independent of the size of the stent, and it has a bioresorbable polymer which allows very fast healing of this stent device.

Key Results

So what we see, that in this all-comer population we see a favourable clinical outcome after PCI using the novel ultra thin Supraflux-Cruz drug-eluting stent. This was non-inferior to the TALENT study, the randomised study, which leads to the use of the Supraflux drug-eluting stent in clinical practice, and for the HBR subgroup of patients within the study, we could show that the Supraflux-Cruz stent was non-inferior for the outcome with the endpoint Doche device orientated clinical outcome in HBR patients.

Take-Home Messages for Practicing Clinicians

So what we see now is where that we have device specific evidence for the use in the broad spectrum of all-comer patients for non-HBR, as well as for HBR patients, to use this novel generation of ultra thin Supraflux-Cruz drug-eluting stent, And for my personal opinion, this is important for every new device to investigate such a device in the highest risk patients we treat every day in the cath lab, and these are HBR patients.

Further Study Needed and Next Steps

As we see in CRUZ-HBR now, the cruz stent seems to be a perfect solution for patient with high bleeding risk and very complex lesions. So the next step would be that on the one hand, you have to challenge this stent in only special situations, For example, CTOs, bifurcations, where this dedicated novel stent can optimise the results, and on the other hand I think this stent opens the possibility to think again about, and minimising the dual antiplatelet therapy, maybe if you use such ultra thin strut stent, it could be enough to treat it after a very clear implantation procedure to treat the patients only with one anti-thrombotic medication, but I think for this unique randomised prospective clinical trials, and I think they are actually in the face of plane.